3P Biopharmaceuticals enters into manufacturing agreement with the Swedish company Affibody

3P Biopharmaceuticals enters into manufacturing agreement with the Swedish company Affibody

The Arrangement Covers Process Transfer, Process Development and GMP Manufacture of Affibody's Candidate

3P Biopharmaceuticals, a leading CDMO specialized in the process development and GMP manufacturing of biologics, has signed a collaboration agreement with the Swedish company Affibody for the process transfer, scale-up and GMP commercial manufacturing of a recombinant protein sole property of Affibody.

According to the agreement, 3P is responsible for transferring and scaling up the process developed by Affibody prior to the execution of the first GMP manufacturing batches. 3P will also perform the process characterization and validation before entering the commercial batch manufacturing stage.

“We are very pleased to be working with Affibody on this project and to create a strong long-term partnership with them. We are sure that this is a mutually beneficial agreement” says Dámaso Molero, General Manager at 3P Biopharmaceuticals.

Besides, “ensuring large scale high quality production of our ABY-035 drug is a natural next step in our evolution as a company with the ambition to have development, manufacturing, and commercialization expertise”, explained David Bejker, CEO of Affibody who added that “the work we have initiated together with 3P is important for us and we look forward to working with 3P.”

This collaboration validates the experience and know-how of 3P’s microbial services in the production of recombinant proteins. Thus, 3P, as a global manufacturing partner, has proven experience in both clinical and commercial production in E.coli included process validation and process characterization.

About Affibody

Affibody is a private clinical-stage Swedish biotech company focused on developing into an integrated biopharma company utilizing next generation biotherapeutics based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

The company operates a focused experimental medicine model and currently has three clinical-stage programs. The first two are therapeutic programs that target psoriasis and rare Immunoglobulin G (IgG)-mediated autoimmune diseases. The third program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer.

In addition to its portfolio of innovative drug projects, the company offers the half-life extension technology, Albumod™, for outlicensing.

Related Content

3P Biopharmaceuticals celebrates its 15th anniversary with Juan Carlos Unzué.

3P Biopharmaceuticals, a Navarre company founded in 2007, met with 370 employees in an exciting and joyful event looking back over its 15 years of trajectory.
Read more

3P Biopharmaceuticals and Biosergen complete together the manufacture of biomass for the Mucormycosis “Black Fungus” clinical phase II trial.

3P Biopharmaceuticals has completed the manufacture of BSG005 biomass planned for its client Biosergen. The client also recently announced Phase II clinical trial of BSG005 against Mucormycosis, otherwise known as the Black Fungus.
Read more

Regional Minister Irujo presents the Navarra Health Cluster

This morning, the Regional Minister for Economic and Business Development, Mikel Irujo, presented the Navarra Health Cluster, seeking to position the region as a European benchmark in personalized medicine, one of the priorities of the S4 Smart Specialisation Strategy. The initiative, which stems from the sector's demand and is led by a driving group, is now open to other companies and entities interested in participating.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.